Skip to main navigation

About
CRISPR/Cas9
Programs & Pipelines
Disease Focus
Patients & Families
Healthcare Professionals
Investors & Media
Careers
- Life @ Intellia
- Join Us
Full-Spectrum Blog
Contact

Full-Spectrum Blog
Contact

About
CRISPR/Cas9
Programs
& Pipelines
Disease
Focus
Patients &
Families
Healthcare
Professionals
Investors &
Media
Careers
- Life @ Intellia
- Join Us

Investors & Media

Investors & Media

Investor Relations

Overview
Press Releases
Scientific Publications & Presentations
Corporate Deck
Events & Presentations
Press Kit
Corporate Governance
Financial Info
Stock Info
Analyst Coverage
Investor Resources

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Nov 12, 2022

Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting

Read More

Events & Presentations

Nov 29, 2022 2:00 PM EST

Piper Sandler 34th Annual Healthcare Conference

Location

New York, NY

Add to Google Calendar

Listen to webcast

Contact IR

Email Alerts

Print Page

Footer Links

Cookie Policy
Terms of Use
Privacy Policy

© Intellia Therapeutics, Inc. 2022

Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.